The Longest Round: NovImmune’s Eight-Year Series B
This article was originally published in Start Up
Several biotechs have kept a private financing round open for several years and extended beyond $100 million, but Swiss antibody firm NovImmune is taking the concept farther than anyone.
You may also be interested in...
The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.
Three $1B+ alliances were penned in July. Topping the list was a potential $2M deal between Skyhawk Therapeutics and Sanofi for the development of novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. Skyhawk will grant Sanofi exclusive worldwide intellectual property rights to candidates discovered and developed under the collaboration. Skyhawk receives $54M up front and is also eligible to receive over $2B in potential milestone payments, as well as potential royalties on future sales. In the top July M&A by deal value, SD Biosensor and a consortium formed with private equity firm SJL Partners agreed to acquire US-based in vitro diagnostics company Meridian Bioscience in an all-cash transaction valued at approximately $1.53B. Founded in 1976, Meridian is a fully integrated life science company that manufactures, markets, and distributes a broad range of diagnostic test kits, purified reagents, and biopharmaceutical enabling technologies. The company has gained expertise through numerous acquisitions over the years including point-of-care testing firm Magellan Biosciences, GenePOC (develops POC molecular diagnostics for infectious diseases), and gastrointestinal diagnostics maker Exalenz Bioscience. Financing reached $3.97bn in biopharma, $851m in device, and $318m in diagnostics.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.